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Abstract
Background: We have previously shown that MUC5B and MUC7 mucins from saliva of HIV negative individuals inhibit
HIV-1 activity by 100% in an in vitro assay. The purpose of this subsequent study was to investigate whether MUC5B
and MUC7 from saliva of HIV patients or with full blown AIDS had a similar inhibitory activity against the virus.
Methods: Salivary MUC5B and MUC7 from HIV patients with different CD4 counts (< 200, 200-400 and > 400) were
incubated with HIV-1 prior to infection of the human T lymphoblastoid cell line (CEM SS cells). Cells were then
cultured and viral replication was measured by a qualitative p24 antigen assay. The size, charge and
immunoreactivity of mucins from HIV negative and positive individuals was also analysed by SDS-PAGE, Western
blot and ELISA respectively.
Results: It was shown that irrespective of their CD4 counts both MUC5B and MUC7 from HIV patients, unlike the
MUC5B and MUC7 from HIV negative individuals, did not inhibit HIV-1 activity. Size, charge and immunoreactivity
differences between the mucins from HIV negative and positive individuals and among the mucins from HIV
patients of different CD4 count was observed by SDS-PAGE, Western blot and ELISA.
Conclusions: Purified salivary mucins from HIV positive patients do not inhibit the AIDS virus in an in vitro assay.
Although the reason for the inability of mucins from infected individuals to inhibit the virus is not known, it is
likely that there is an alteration of the glycosylation pattern, and therefore of charge of mucin, in HIV positive
patients. The ability to inhibit the virus by aggregation by sugar chains is thus diminished.
Background
Several in vitro studies have shown that human saliva
inhibits the activity of Human Immunodeficiency Virus
(HIV) [1-3] the causative agent of Acquired Immunodefi-
ciency Syndrome (AIDS). We hypothesized and con-
firmed that salivary MUC5B and MUC7 [4], breast milk
mucin (MUC1) [5] and cervical or pregnancy plug
mucins [6] inhibited HIV-1 activity in an in vitro inhibi-
tion assay. We have also shown the inhibition of poxvirus
activity by MUC1 [7]. With this in mind, we decided to
investigate whether MUC5B and MUC7 from saliva of
HIV patients or with full blown AIDS had a similar inhi-
bitory activity, as the MUC5B and MUC7 from HIV
negative individuals [4], against the virus. Although there
have been documented cases of transmission of HIV
through the exchange of oral fluids, this is indeed very
rare and confined to a small group of those with ulcera-
tions or injuries to the mucosal lining of the mouth (per-
sonal communication, David Coetzee, UCT).
In this assay a subtype D HIV-1 virus which was first
isolated in February 1988 from an AIDS patient and char-
acterised by the Department of Medical Virology, Tyger-
berg Hospital, Cape Town, South Africa, was used.
Incubation of the virus with CEM-SS cells which expresses
CD4, CXCR4, ICAM-3 and MHC class II molecules [8]
results in the latter forming syncitia upon infection [9].
Results
Mucin preparation, purification, identification and
analysis
As described by Habte et al. [4], the SDS-PAGE band
appearance, Western blotting and amino acid analysis
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and included volumes of the Sepharose CL-4B gel filtra-
tion column to be MUC5B and MUC7 respectively.
Toxicity assay
Prior to the inhibition assay, the toxicity of salivary
MUC5B and MUC7 mucins from HIV patients with
CD4 count (< 200, 200-400 and > 400) to the CEM SS
cells was determined by toxicity assay. As shown in
Table 1, there was death of 5% of the cells when incu-
bated with MUC5B from patients with CD4 count 200-
400. Other than that, there was no toxic effect of any
mucin to the CEM SS cells.
Inhibition assay
To check whether the salivary MUC5B and MUC7
mucins from HIV patients possess the same inhibitory
activity as those from HIV negative individuals [4], the
anti-HIV-1 activities of the salivary MUC5B and MUC7
mucins from the three groups of HIV patients (i.e.
patients with CD count < 200, 200-400 and > 400) was
determined in an in vitro inhibition assay. The result
demonstrated that irrespective of their CD4 count both
MUC5B and MUC7 mucins from HIV patients, unlike
those HIV negative patients, failed to inhibit HIV-1
activity and a 100% viral infection of the CEM SS cells
was measured by the p24 antigen assay after a 30 min
incubation period (Figure 1A-C). This was unlike
MUC5B and MUC7 mucins from HIV negative indivi-
duals [4]. When HIV-1 was treated with the media
instead of mucins as a control, 100% HIV-1 replication
or infection of the CEM SS cells was detected (Figure
1A, B and 1C). However, no HIV-1 infection was seen
when heat inactivated HIV-1 was used (Figure 1A, B
and 1C).
The effect of the length of the incubation period on
the rate of inhibition of the HIV-1 infection of the CEM
SS cells was determined by incubating the CEM SS cells
with the mixtures for 1 h and 2 h. There was no differ-
ence due to the length of the incubation period (Figure
1A, B and 1C). As in the case of the MUC5B and
MUC7 from HIV negative individuals [4], serial tenfold
dilution, (10
-1 to 10
-4) of the MUC5B and MUC7
mucins, starting at 0.9 mg mucin, from HIV patients of
all the different CD4 counts (< 200, 200-400 and > 400)
were done in triplicate and this made no difference to
infectivity (data not shown).
To determine if the salivary MUC5B and MUC7
mucins from HIV positive patients trap or aggregate the
v i r u s e sa st h eM U C 5 Ba n dM U C 7m u c i n sf r o mH I V
negative individuals did [4] the mixtures were filtered
through 0.45 μm pore size cellulose acetate filter at the
end of the incubation period (60 min), and the filtrates
were subsequently incubated with the CEM SS cells for
30 min. Unlike the filtrates from the mixtures of HIV-1
plus MUC5B and MUC7 from HIV negative individuals
[4], these filtrates caused 100% viral infection of the
CEM SS cells (Figure 2A, B and 2C). Even if these fil-
trates were incubated with the CEM SS cells for 1 h and
2h ,n oc h a n g ef r o mt h ea b o v er e s u l t sw a so b s e r v e d
(Figure 2A, B and 2C).
Gradient gel analyses
To assess if the HIV infection induced any structural or
size difference on the salivary MUC5B and MUC7
mucins, salivary MUC5B and MUC7 mucins from HIV
positive individuals with different CD4 counts (< 200,
200-400 and > 400), were dissolved in a gel loading buf-
fer and were subjected to a 4-20% gradient gel alongside
the salivary MUC5B and MUC7 mucins from HIV nega-
tive individuals as a control (Figure 3).
The PAS stained gel showed that the MUC5B from
normals had slightly more material in the stacking gel
and less penetration into the running gel (lane 1) than
that from the HIV patients with CD4 count < 200 (lane
2), 200-400 (lane 3) and > 400 (lane 4) which showed
less material in the stacking gel and high penetration
into the running gel. MUC5B from patients with CD4
count < 200 (lane 2) appeared as a broader band on the
top of the running gel. The MUC7a from normals had
slightly more material and showed less penetration into
the running gel (lane 5) than that from the HIV patients
with CD4 count < 200 (lane 6), 200-400 (lane 7) and
> 400 (lane 8) which showed slightly less material of
MUC7a and more material of MUC7b than the normal.
The MUC7a from patients with CD4 count > 400 (lane
8) showed less material than the rest.
Immunoreactivity analyses
To determine if there are any immunoreactivity differ-
ences between salivary MUC5B and MUC7 mucins
Table 1 Mucin toxicity
Sample Con CEM SS
cells
% of dead
cells
% of live
cells
MUC5B CD4 < 200 0.9
mg
2.5 × 10
6/
ml
0 100
MUC5B CD4 < 200-
400
0.9
mg
2.5 × 10
6/
ml
59 5
MUC5B CD4 < 400 0.9
mg
2.5 × 10
6/
ml
0 100
MUC7 CD4 < 200 0.9
mg
2.5 × 10
6/
ml
0 100
MUC7 CD4 < 200-
400
0.9
mg
2.5 × 10
6/
ml
0 100
MUC7 CD4 < 400 0.9
mg
2.5 × 10
6/
ml
0 100
Toxicity of salivary MUC5B and MUC7 mucins from HIV patients with CD4
count (< 200, 200-400 and > 400) to the CEM SS cells.
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Page 2 of 9from HIV negative and HIV positive individuals towards
the same antibodies as the result of the HIV infection,
salivary MUC5B and MUC7 mucins from HIV positive
individuals with different CD4 counts (< 200, 200-400
and > 400) were coated in an ELISA plate alongside the
salivary MUC5B and MUC7 from HIV negative indivi-
duals and probed with anti-MUC5B and anti-MUC7
polyclonal antibodies (Figure 4).
Although the difference in immunoreactivity between
mucins from HIV negative and positive samples is very
small, MUC5B (Figure 4A) and MUC7 (Figure 4B) from
HIV negative individuals have shown the highest reactiv-
ity towards their respective antibodies. Interestingly, we
detected immunoreactivity differences between the
mucins from HIV patients of different CD4 counts as
well. However, none of these differences were significant.
Figure 1 Anti-HIV-1 activities of salivary MUC5B and MUC7 of different CD4 counts for unfiltered samples. Salivary MUC5B and MUC7
mucins (500 μl or 0.9 mg each) from patients with CD4 count (< 200, 200-400 and > 400) were incubated with subtype D HIV-1 for 60 min and
filtered through 0.45 μm pore size cellulose acetate filter. As controls HIV-1 treated with media and heat inactivated HIV-1 were used. The
unfiltered samples were then incubated with CEM SS cells at a concentration of 0.5 × 10
6cells/ml for 30 min, 1 h and 2 h. After PBS wash cells
were cultured and viral replication was measured by a qualitative p24 antigen assay. Letters A, B and C indicate the anti-HIV-1 activity of salivary
MUC5B and MUC7 mucins from HIV patients with CD4 counts < 200, 200-400 and > 400 respectively.
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To determine if there are any charge differences between
the salivary MUC5B and MUC7 mucins from HIV nega-
tive and HIV positive individuals or among the mucins
from HIV patients of different CD4 counts, MUC5B and
MUC7 mucins from HIV positive individuals with differ-
ent CD4 counts (< 200, 200-400 and > 400) were run in
an agarose gel alongside the MUC5B and MUC7 from
HIV negative individuals as a control. Mucins were then
transferred to nitrocellulose membranes and probed with
polyclonal rabbit anti-MUC5B and monoclonal mouse
anti-MUC7 antibodies (Figure 5).
The MUC5B from HIV negative individual (lane 4)
clearly had more material and a wide range of charge
after equal loading, than the MUC5B from the HIV
positive patients with CD4 count > 400 (lane 1), 200-
400 (lane 2) and < 200 (lane 3) which showed a rela-
tively small range of charge. The mobilities between
groups hardly differed (lanes 1-5).
Differences in the charge was observed between the
MUC7 from HIV negative and HIV positive individuals
and within the group of HIV patients of different CD4
counts (lanes 7-10). MUC7 from HIV negative indivi-
duals (lane 10) was of lower charge than the MUC7
Figure 2 Anti-HIV-1 activities of salivary MUC5B and MUC7 of different CD4 counts for filtrates. The rest is as for Fig 1.
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7), 200-400 (lane 8) and < 200 (lane 9). As shown in the
figure, the crude saliva positive controls reacted with the
anti-MUC5B and anti-MUC7 antibodies (lanes 5 and
1 1 )a se x p e c t e d ,w h i l s tt h en e g a t i v ec o n t r o lf o rM U C 7
(lane 6) and for MUC5B (lane 12) did not react with the
anti-MUC5B and anti-MUC7 antibodies respectively.
Discussion
Although HIV-1 subtype C is currently the most preva-
lent in South Africa, the subtype D virus used in this
study was found during the early stages of the HIV epi-
demic and is currently prevalent here, albeit less fre-
quently. This subtype D virus is the only lab adapted
strain we had available to us in the vicinity of Cape
Town, in possibly the only laboratory based HIV assay
in the country. The CEM-SS cells, which were used in
this experiment, are known to produce distinct and
repeatable syncytia formation when infected with HIV-1.
These cells are capable of developing easily quantifiable
syncytia formation in four to six days upon the addition
of HIV-1 [9] and are reported to express CD4, CXCR4,
ICAM-3 and MHC class II molecules [8], and thus
c o u l db ec o n s i d e r e das u i t a b l em o d e la sH I V - 1h o s t
cells.
Previously we have shown that salivary MUC5B and
MUC7 mucins from HIV negative individuals inhibited
HIV-1 activity by 100% [4]. Here we investigated
whether salivary MUC5B and MUC7 from HIV positive
individuals would have a similar inhibitory effect to that
from HIV negative individuals in an in vitro inhibitory
assay. We have shown that irrespective of their CD4
count (< 200, 200-400 and > 400) both MUC5B and
MUC7 mucins from HIV patients failed to inhibit HIV-
1 activity. There was a 100% infection of the CEM SS
cells as detected by the p24 antigen assay. Although the
reason is not clear, it is possible that HIV infection
induces changes of the salivary glands which results in a
decline in the amount of saliva and a change in its con-
stituents [10]. This in turn may affect the glycosylation
pattern or sugar composition of the salivary mucins, and
if inhibition of the virus is through aggregation by the
Figure 3 Gradient gel analysis of salivary MUC5B and MUC7
mucins from HIV negative and positive individuals. Freeze-dried
samples (30 μg) of MUC5B from HIV negative individual (lane 1),
MUC5B from HIV positive individuals with CD4 counts < 200 (lane
2), 200-400 (lane 3), > 400 (lane 4), MUC7 from HIV negative
individual (lane 5), MUC7 from HIV positive individuals with CD4
counts < 200 (lane 6), 200-400 (lane 7) and > 400 (lane 8) were
prepared in a gel loading buffer and separated in a 4-20% gradient
gel. Following electrophoresis the gel was stained with PAS. While
arrows in red indicates the two glycoforms of MUC7 on top of the
running gel (MUC7a) and slightly entering the running gel (MUC7b),
the arrow in black is at the start of running gel.
Figure 4 ELISA monitoring immunoreactivity of salivary
MUC5B and MUC7 mucins from HIV negative and positive
individuals. Plate (A) was coated with MUC5B from HIV negative
individual (dark blue diamond), MUC5B from HIV positive individuals
with CD4 counts < 200 (pink square), 200-400 (blue triangle) and >
400 (pale blue cross) and plate (B) was coated with MUC7 from HIV
negative individual (dark blue diamond), MUC7 from HIV positive
individuals with CD4 counts < 200 (pink square), 200-400 (blue
triangle) and > 400 (pale blue cross). Plates were incubated with
serial two-fold dilutions of goat anti-MUC5B (A) and goat anti-MUC7
(B) polyclonal antibodies at concentrations between 8 μg/ml and
0.25 μg/ml (goat anti-MUC5B) and 12 μg/ml and 0.375 μg/ml (goat
anti-MUC7). Antibody binding was detected using rabbit anti-goat
HRPO linked secondary antibody and visualized with TMB/H2O2
substrate. Absorbance values were read at 405 nm in a Titertek
ELISA reader. Each point is the average absorbance of duplicate
samples. As a negative control wells were coated with PBS (+).
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Page 5 of 9carbohydrate side chains, and if changes in these sugar
side chains occurs as a result of infection [11], it is con-
ceivable that this is the reason for the inability of
mucins from HIV positive individuals to inhibit the
virus in an invitro assay. Furthermore HIV infection is
also reported to suppress the production of saliva inhibi-
tory factors, or elicit blocking molecules [12]. Mucins
are also reported to lose their carbohydrate side chains
as a result of infections which could affect their ability
to adhere or recognize antigens or micro-organisms
[13]. Thus there is a higher possibility that the HIV
infection induced change in the glycosylation pattern of
the mucins.
To check whether the HIV infection affected the abil-
ity of the mucins to trap or aggregate the virus, the fil-
trates of the mixtures were incubated with the CEM SS
cells. The filtrates caused 100% infection of the CEM SS
cells, unlike the filtrates from the mixtures of HIV-1
and normal mucins [4]. This suggests that both MUC5B
and MUC7 mucins from HIV positive individuals, irre-
spective of their CD4 count failed to aggregate the virus.
Hence there were free viruses in the filtrates that could
enter the CEM SS cells and cause infection. As the car-
bohydrate moieties of salivary mucins serve as attach-
ment sites for bacteria and viruses [14,15], changes in
charge or glycosylation pattern as a result of HIV infec-
tion could affect the ability of the mucins to aggregate
the virus.
The PAS stained 4-20% gradient gel demonstrated
t h a tt h e r ew a sas i z ed i f f e r e n c eb e t w e e nt h em u c i n s
from HIV negative and positive individuals as well as
between the mucins from HIV patients of different CD4
counts, with the mucins from HIV positive individuals
showing slightly more penetration or higher electro-
phoretic mobility. Again changes in the glycosylation
pattern could be implicated. Furthermore, as the degree
of glycosylation affects the electrophoretic mobility
[16,17], the appearance of the mucins from HIV nega-
tive and positive individuals on the gradient gel were
different. It should be noted that any population of
mucins exhibit polydispersity and even heterogeneity
with respect to size, and coupled with their extensive
glycosylation, they appear as smears on SDS-PAGE gels
and display different electrophoretic mobilities. In sum-
mary, as the structural differences in mucins are related
to physiologically different functions [18], the size or
structural difference of the salivary mucins from HIV
patients may affect their ability to trap or aggregate the
virus. However, the differences we detected were too
small to form any conclusion.
Enzyme linked immunosorbent assay (ELISA) was also
performed to determine if the immunoreactivity of the
salivary mucins was altered due to the HIV infection. As
shown in the result section immunoreactivity differences
between mucins from HIV negative and positive indivi-
duals was observed, with both MUC5B and MUC7
mucins from HIV negative individuals showing the high-
est reactivity. If not for the shortage of antibody, better
immunoreactivity difference between MUC7 mucins
from HIV negative and positive individuals could have
been shown by increasing the concentration of the pri-
mary antibody. Although the reason is not clear, as var-
iation in glycosylation can affect antibody binding [17],
the HIV infection may have affected the glycosylation
pattern of the mucins which could result in epitope
modification.
Western blotting has shown varying mobility of
MUC5B and especially MUC7 from normals and HIV
patients of different CD4 counts on an agarose gel.
Mucins of higher charge migrate further into the gel than
those of lower charge [19]. The MUC7 from positive
patients migrated further than that from normal indivi-
duals. Therefore, these diseased species of MUC7 were
more highly charged than normal MUC7. If this is due to
an altered glycosylation then one can expect shorter side
chains and an exposure of more charged groups on the
mucin, with a consequent increase in the charge per den-
sity ratio of the mucin. It wou l da l s ob ee x p e c t e dt h a t
MUC7 from patients with a CD4 count > 400 would
migrate closer to where normal MUC7 is positioned. Sur-
prisingly this was not to be the case because it seemed
like the mobility of MUC7 from patients with CD4 < 200
(Figure 5, lane 9) migrated less than CD4 200-400 (lane
8) and CD4 > 400 (lane 7). Also the gels could be over-
loaded and thus we have not highlighted the mobility of
the different mucins adequately.
T h er o l eo fs a l i v a r yM U C 5 Ba n dM U C 7i np r o t e c t i n g
the oral cavity from bacteria, viruses, yeasts, and toxins
is well documented [14,20-22]. However, Lal et al. [11]
reported that compared to HIV negative individuals, sal-
iva from HIV positive individuals possess considerably
lower anti-candicidal activity. This was supported by the
findings of Gururaja et al. [23] and Situ et al. [24] that
fungal infections specifically Candida albicans has
increasingly colonized the oral cavity of HIV positive
patients. This suggested that the HIV infection may
have induced functional alteration on the salivary
mucins which are very potent in normal circumstances.
For instance MUC7 in immunocompromised individuals
is reported to lose the expression of sugar receptor
(sLe
x) hence making the individual more susceptible to
oral diseases [25]. Furthermore, as covalently modified
MUC7 is reported to lose its potency against Pseudomo-
nas aeruginosa, Staphylococcus aureus and Candida
albicans [20], the idea that HIV infection might induce
structural changes to the mucins is perhaps a possibility.
In summary the SDS-PAGE (gradient gel), ELISA and
Western blot analysis strengthens these findings.
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of patient recruitment, volume of saliva obtained from
individual patients and the disruption of clinical services
in a busy clinic with limited resources. The yield of
MUC5B and MUC7 from a single sample was far too little
and saliva samples from ten donors “for each CD4 group”
had to be pooled to a final volume of approximately 10.0
ml for each group in this study. A broader study is
required for statistical verifiability. The use of different
HIV-1 strains in the in vitro assay is also necessary.
Conclusions
In summary, irrespective of their CD4 count (< 200, 200-
400 and > 400) both MUC5B and MUC7 mucins from
HIV patients did not inhibit HIV-1 activity. Size, charge
and immunoreactivity differences between the mucins
from HIV negative and positive individuals and among
the mucins from HIV patients of different CD4 count
was observed by gradient gel, ELISA and Western blot.
Methods
Ethics
The University of Cape Town Research and Ethics
Committee approved this study (ethics approval number
REC REF: 283/2004).
Materials
The CEM SS cells were from AIDS Research and Refer-
ence Reagent Programme (Germantown, USA). The p24
antigen kit was from Vironostika HIV-1 Antigen kit
Biomérieux (France). Monoclonal mouse anti-MUC7
(EU-MUC7a) was kindly provided by Dallas Swallows
(University College London, UK). Polyclonal rabbit anti-
MUC5B (LUM5B-2) and goat anti-rabbit horse radish
peroxidise (HRPO) linked secondary antibodies were
kindly provided by Sara Kirkham (Manchester, UK).
Polyclonal goat anti-MUC5B (sc-23024), anti-MUC7
(sc-16918) and rabbit anti-goat HRPO linked secondary
antibodies were from Santa Cruz (California). Goat anti-
mouse HRPO linked secondary antibody was from
Novocastra (Newcastle, UK).
Saliva collection
Saliva was collected from HIV positive female volunteers
from the clinic of infectious diseases in Groote Schuur
Hospital, Cape Town, South Africa. The production of
saliva was stimulated by chewing on parafilm and col-
lected into 10 ml of 6 M GuHCl containing a cocktail of
protease inhibitors such as 10 mM EDTA, 5 mM NEM, 1
mM PMSF and 0.1% CHAPS, pH 6.5. Samples were col-
lected into cooled containers on ice and stored at -20°C.
Samples were grouped into three categories according to
the CD4 counts of the patients, less than 200, between
200 and 400 and greater than 400. The volume of saliva
produced by each individual varied. Saliva was pooled in
3 groups according to the CD4 counts, to a final volume
of approximately 10.0 ml per group. The patients with
CD4 count < 200 had full blown AIDS.
Figure 5 Western blotting of salivary MUC5B and MUC7 from HIV positive individuals with different CD4 counts. Lane 1, MUC5B from
patients with CD4 > 400, lane 2, MUC5B from patients with CD4 200-400, lane 3, MUC5B from patients with CD4 < 200, lane 4, MUC5B from HIV
negative individual, lane 5, crude saliva (positive control), lane 6, MUC7 (negative control), lane 7, MUC7 from patients with CD4 > 400, lane 8,
MUC7 from patients with CD4 200-400, lane 9, MUC7 from patients with CD4 < 200, lane 10, MUC7 from HIV negative individuals, lane 11, crude
saliva (positive control) and lane 12, MUC5B (negative control) were separated by a 1% agarose gel and transferred to nitrocellulose membrane.
Following overnight blocking, the membranes were incubated for 2 h with rabbit anti-MUC5B polyclonal (lanes 1-6) and mouse anti-MUC7
monoclonal (lanes 7-12) antibodies diluted in 5% (m/v) low fat milk powder in TBST at 1 in 2000 (rabbit anti-MUC5B) and 1 in 1000 (mouse anti-
MUC7). Membranes were then washed 3 × 5 min with TBST and incubated for 1 h with HRPO linked goat anti-rabbit (lanes 1-6) and goat anti-
mouse (lanes 7-12) secondary antibodies diluted in 5% (m/v) low fat milk powder in TBST at dilutions of 1 in 5000 and 1 in 1500 respectively.
After another TBST wash (3 × 5 min), bands were detected using an ECL detection kit.
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analysis
The preparation and purification of salivary mucins was
done according to the method described by Habte et al.
[4]. Briefly, each mucin pool was separated by gel filtration
on Sepharose CL-4B and subsequently purified by caesium
chloride isopycnic density gradient ultra-centrifugation
[26]. Mucins were further analysed by SDS-PAGE [27],
identified by Western blotting [28] and amino acid analy-
sis [29,30]. Glycoprotein was estimated by the PAS proce-
dure of [31] and protein according to the method of
Lowry et al. [32].
Enzyme linked immunosorbent assay
Salivary MUC5B and MUC7 from HIV negative and
HIV positive individuals with different CD4 counts
(< 200, 200-400 and > 400) were coated (10 μg/ml) in
PBS (150 μlp e rw e l l ,o v e r n i g h ta t4 ° C ) .N o n - s p e c i f i c
binding of the antibodies was prevented by blocking the
wells with 0.5% BSA-PBS (200 μl, 1 h at 37°C) and the
plates were washed three times with PBS-Tween. Serial
two-fold dilutions of primary antibodies starting from
8 μg/ml (goat anti-MUC5B) and 12 μg/ml (goat anti-
MUC7) were added to the plate in 0.5% BSA-PBS and
incubated (100 μl, 2 h at 37°C). The plates were washed
three times with PBS-Tween and rabbit anti-goat HRPO-
linked secondary antibody (1 in 5000 in 0.5% BSA-PBS)
was added to each well and incubated (120 μl, 1 h at
37°C). Following three washes with PBS-Tween, 150 μlo f
the substrate solution (TMB in 0.15 M citrate-phosphate
buffer, pH 5.0) was added to each well and the colour
was allowed to develop in the dark against the back-
ground of the controls (10-15 min) and the A405 of each
well was measured in a Titertek ELISA plate reader. As a
control, wells were coated with PBS.
Toxicity assay
The toxicity of salivary MUC5B and MUC7 from HIV
positive individuals with different CD4 counts (< 200,
200-400 and > 400) to the phytohaemagglutinin (PHA)
stimulated CEM SS cells was determined by toxicity
assay. Briefly 500 μl of the CEM SS cells in RPMI com-
plete containing 10% Fetal Calf Serum, 1% Penicillin/
Streptomycin antibiotic, 10 μmol Fungin and 50 μmol
2-mercaptoethanol (final concentration 2.5 × 10
6 cells/
ml) was incubated with 250 μlo fI L - 2a n d2 5 0μl( 0 . 9
mg) of MUC5B and MUC7 with different CD4 counts
(< 200, 200-400 and > 400) in CO2 incubator for 24 h.
As controls CEM SS cells with IL-2 only and IL-2 with-
out CEM SS cells (blank) were used. After spinning at
200 g for 5 min cells were resuspended in 500 μlo f
RPMI and live and dead cells were counted using Try-
pan blue exclusion criteria. The percentage of viable
cells was calculated as live cells/total cells × 100.
HIV inhibition assay
The anti-HIV-1 activities of salivary MUC5B and MUC7
from HIV positive individuals were tested in an inhibition
assay according to the method of Nagashunmugam et al.
[33]. Briefly MUC5B and MUC7 with different CD4
counts (< 200, 200-400 and > 400) were dissolved in
0.25% PBS and (500 μl or 0.9 mg each) were mixed with
4 ml of the subtype D HIV-1 supernatant fluid (SNF), at
the same titer of virus used in the previous study [4] and
incubated for 60 min at 37°C separately. As controls, heat
inactivated HIV-1 or HIV-1 plus media (RPMI 1640 with
10% Fetal Calf Serum and IL-2) were used. At the end of
the incubation period the mixtures (HIV-1 plus MUC5B
from HIV patients with CD4 count < 200), (HIV-1 plus
MUC5B from HIV patients with CD4 count between 200
and 400), (HIV-1 plus MUC5B from HIV patients with
CD4 count > 400), (HIV-1 plus MUC7 from HIV patients
with CD4 count < 200), (HIV-1 plus MUC7 from HIV
patients with CD4 count between 200 and 400), (HIV-1
plus MUC7 from HIV patients with CD4 count > 400)
and the control (HIV-1 plus media) were filtered through
0.45 μm pore size cellulose acetate filter (25 mm dia-
meter) and both the unfiltered and filtered samples were
incubated with the CEM SS cells at 37°C at a concentra-
tion of 0.5 × 10
6 cells/ml for 30 min, 1 h and 3 h. Cells
were then washed three times with PBS to remove free
virus and cultured. Supernatant fluid was harvested on
Day 4 and viral replication was measured by a qualitative
p24 antigen assay. Endpoints were calculated by the
Reed-Muench formula and the 50% tissue culture infec-
tive dose (TCID50) was expressed as the highest dilution
that produced a positive qualitative p24 antigen result.
All samples were done in triplicate and the anti-HIV-1
activity of each sample was tested in a serial tenfold dilu-
tion (10
-1 to 10
-4).
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